AU2001236005A1 - Preparations stabilized over long time - Google Patents
Preparations stabilized over long timeInfo
- Publication number
- AU2001236005A1 AU2001236005A1 AU2001236005A AU3600501A AU2001236005A1 AU 2001236005 A1 AU2001236005 A1 AU 2001236005A1 AU 2001236005 A AU2001236005 A AU 2001236005A AU 3600501 A AU3600501 A AU 3600501A AU 2001236005 A1 AU2001236005 A1 AU 2001236005A1
- Authority
- AU
- Australia
- Prior art keywords
- long time
- over long
- stabilized over
- preparations stabilized
- preparations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-53310 | 2000-02-29 | ||
JP2000053310 | 2000-02-29 | ||
PCT/JP2001/001524 WO2001064241A1 (en) | 2000-02-29 | 2001-02-28 | Preparations stabilized over long time |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001236005A1 true AU2001236005A1 (en) | 2001-09-12 |
Family
ID=18574710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001236005A Abandoned AU2001236005A1 (en) | 2000-02-29 | 2001-02-28 | Preparations stabilized over long time |
Country Status (5)
Country | Link |
---|---|
US (1) | US7163671B2 (en) |
EP (1) | EP1260230A4 (en) |
JP (1) | JP4683810B2 (en) |
AU (1) | AU2001236005A1 (en) |
WO (1) | WO2001064241A1 (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7112409B2 (en) * | 1999-01-29 | 2006-09-26 | Center For Molecular Medicine And Immunology | Method of determining cytokine dosage for myelosuppressive state |
RS51292B (en) * | 2000-05-15 | 2010-12-31 | F. Hoffmann-La Roche Ag. | NEW PHARMACEUTICAL MIXTURE |
CA2417960C (en) | 2000-08-04 | 2012-07-10 | Dmi Biosciences, Inc. | Method of using diketopiperazines and composition containing them |
DE60229961D1 (en) * | 2001-08-29 | 2009-01-02 | Chugai Pharmaceutical Co Ltd | ANTIBODIES CONTAINING STABILIZED PREPARATIONS |
SI21258A (en) * | 2002-07-17 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Stable pharmaceutical preparation containing erythropoietin and poloxamer polyol |
EP1541165A4 (en) * | 2002-08-27 | 2009-06-24 | Chugai Pharmaceutical Co Ltd | Method of stabilizing protein solution preparation |
KR20050089857A (en) * | 2002-12-26 | 2005-09-08 | 아지노모토 가부시키가이샤 | Inhibitor for liver cancer onset and progress |
EP2537524B1 (en) | 2003-05-15 | 2016-07-06 | Ampio Pharmaceuticals, Inc. | Treatment of T-cell mediated diseases |
BRPI0411114B8 (en) * | 2003-06-10 | 2021-05-25 | Lg Chemical Ltd | stable aqueous solution of human erythropoietin, not containing serum albumin |
US7141544B2 (en) * | 2003-10-10 | 2006-11-28 | Baxter International, Inc. | Stabilization of pharmaceutical protein formulations with small peptides |
MY139088A (en) * | 2005-02-21 | 2009-08-28 | Lg Life Sciences Ltd | Sustained release composition of protein drug |
WO2008068885A1 (en) * | 2006-11-30 | 2008-06-12 | Sanyo Chemical Industries, Ltd. | Protecting agent for use in lyophilization and method for production of physiologically active substance |
JP5513380B2 (en) * | 2007-06-25 | 2014-06-04 | アムジエン・インコーポレーテツド | Composition of specific binding agents for hepatocyte growth factor |
JP4812807B2 (en) * | 2007-06-27 | 2011-11-09 | 三洋化成工業株式会社 | Protein-containing aqueous solution stabilizer and method for stabilizing protein-containing aqueous solution |
UA98001C2 (en) | 2007-08-27 | 2012-04-10 | Биодженерикс Аг | Liquid formulation of g-csf conjugate |
ES2962777T3 (en) * | 2007-11-15 | 2024-03-21 | Amgen Inc | Antioxidant-stabilized aqueous antibody formulation for parenteral administration |
AU2008343052A1 (en) | 2007-12-21 | 2009-07-09 | Lyotropic Therapeutics, Inc. | Stabilized formulations of peptides and proteins |
PE20091174A1 (en) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT |
WO2009146320A1 (en) | 2008-05-27 | 2009-12-03 | Dmi Life Sciences, Inc. | Therapeutic methods and compounds |
CA2734275A1 (en) * | 2008-09-10 | 2010-03-18 | Genentech, Inc. | Compositions and methods for the prevention of oxidative degradation of proteins |
SI3345615T1 (en) | 2010-03-01 | 2020-03-31 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
CN103841934A (en) | 2011-10-10 | 2014-06-04 | 安皮奥制药股份有限公司 | Implantable medical devices for enhancing immune tolerance and methods of making and implanting the same |
EP2766029B1 (en) | 2011-10-10 | 2020-03-25 | Ampio Pharmaceuticals, Inc. | Treatment of degenerative joint disease |
US10881710B2 (en) | 2011-10-28 | 2021-01-05 | Ampio Pharmaceuticals, Inc. | Treatment of rhinitis |
CN104350064A (en) | 2012-03-14 | 2015-02-11 | 耶达研究及发展有限公司 | Modified kisspeptin peptides and uses thereof |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
ES2688895T3 (en) * | 2013-03-13 | 2018-11-07 | F. Hoffmann-La Roche Ag | Formulations with reduced oxidation |
AR095399A1 (en) | 2013-03-13 | 2015-10-14 | Genentech Inc | FORMULATIONS WITH REDUCED OXIDATION, METHOD |
US20140314778A1 (en) | 2013-03-13 | 2014-10-23 | Genentech, Inc. | Formulations with reduced oxidation |
SG10201707619RA (en) | 2013-03-15 | 2017-10-30 | Ampio Pharmaceuticals Inc | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same |
WO2016028790A1 (en) | 2014-08-18 | 2016-02-25 | Ampio Pharmaceuticals, Inc. | Treatment of joint conditions |
AU2016215070B2 (en) * | 2015-02-06 | 2020-09-24 | Latitude Pharmaceuticals, Inc. | Aqueous solution formulations of vancomycin |
EP3310375A4 (en) | 2015-06-22 | 2019-02-20 | Ampio Pharmaceuticals, Inc. | USE OF LOW MOLECULAR WEIGHT HUMAN SERUM ALBUMIN FRACTIONS FOR TREATING DISEASES |
UA123679C2 (en) | 2016-05-27 | 2021-05-12 | Іпсен Біофарм Лімітед | LIQUID NEUROTOXIN COMPOSITION STABILIZED BY TRYPTOPHANE OR TYROSINE |
CN119120371A (en) * | 2024-11-13 | 2024-12-13 | 知佰幸细胞库(浙江)有限公司 | Composition for promoting cell regeneration and application thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56154419A (en) * | 1980-04-30 | 1981-11-30 | Green Cross Corp:The | Heat treatment of alpha-fetoprotein-containing aqueous solution |
JPS6197229A (en) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | Stable erythropoietin preparation |
JP2577742B2 (en) | 1986-07-18 | 1997-02-05 | 中外製薬株式会社 | Stable granulocyte colony-stimulating factor containing preparation |
GR871067B (en) * | 1986-07-18 | 1987-11-19 | Chugai Pharmaceutical Co Ltd | Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor |
JP2577743B2 (en) * | 1986-07-18 | 1997-02-05 | 中外製薬株式会社 | Stable granulocyte colony-stimulating factor containing preparation |
JP2577744B2 (en) * | 1986-07-18 | 1997-02-05 | 中外製薬株式会社 | Stable granulocyte colony-stimulating factor containing preparation |
JPH02116515A (en) | 1988-10-26 | 1990-05-01 | Matsushita Electric Works Ltd | Manufacture of inorganic building material |
JP2732091B2 (en) | 1988-10-31 | 1998-03-25 | キヤノン株式会社 | Video signal processing device |
JPH0768137B2 (en) * | 1989-06-15 | 1995-07-26 | 株式会社ミドリ十字 | Albumin preparation and manufacturing method thereof |
JP2949846B2 (en) * | 1990-11-30 | 1999-09-20 | 吉富製薬株式会社 | How to store albumin preparations |
US5272135A (en) * | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
JPH0768137A (en) | 1993-09-02 | 1995-03-14 | Dow Chem Japan Ltd | Separation membrane module |
JPH10265404A (en) * | 1996-02-02 | 1998-10-06 | Mitsui Chem Inc | Pharmaceutical preparation containing human growth hormone |
TW518219B (en) * | 1996-04-26 | 2003-01-21 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
JP2000247903A (en) | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | Long-term stabilized pharmaceutical preparation |
-
2001
- 2001-02-28 US US10/220,523 patent/US7163671B2/en not_active Expired - Lifetime
- 2001-02-28 WO PCT/JP2001/001524 patent/WO2001064241A1/en active Application Filing
- 2001-02-28 AU AU2001236005A patent/AU2001236005A1/en not_active Abandoned
- 2001-02-28 JP JP2001563138A patent/JP4683810B2/en not_active Expired - Fee Related
- 2001-02-28 EP EP01908161A patent/EP1260230A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US7163671B2 (en) | 2007-01-16 |
WO2001064241A1 (en) | 2001-09-07 |
JP4683810B2 (en) | 2011-05-18 |
US20030092622A1 (en) | 2003-05-15 |
EP1260230A1 (en) | 2002-11-27 |
EP1260230A4 (en) | 2008-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001236005A1 (en) | Preparations stabilized over long time | |
AU2001294192A1 (en) | Solid preparations | |
AU2001277781A1 (en) | Stabilized antibody-containing preparations | |
AU2001232799A1 (en) | Protein c derivatives | |
AU2000267458A1 (en) | Hypercomputer | |
AU2001254546A1 (en) | Aminopiperidines | |
AU2001220246A1 (en) | Neckphone | |
AU2001239310A1 (en) | Decahydro-isoquinolines | |
AU2001282607A1 (en) | Solution preparations stabilized over long time | |
AU2001258349A1 (en) | Bisacylguanidine | |
AU8260701A (en) | Solution preparations stabilized over long time | |
AU2001242479A1 (en) | Proliposomal encapsulated preparations | |
AU2001258924A1 (en) | Microsatellite-aflp | |
AU2001240791A1 (en) | Sequence | |
AU2001259450A1 (en) | Cytoskeleton-associated proteins | |
AU2001288102A1 (en) | Solid preparations | |
AU2001246864A1 (en) | Hypotensors | |
AU2001282521A1 (en) | OCT preparations | |
AU2001272427A1 (en) | Solid preparations | |
AU2001226668A1 (en) | Crankshaft-starter-generator | |
AU2001244863A1 (en) | Apoptin-associating protein | |
AU2002239747A1 (en) | Cystoskeleton-associated proteins | |
AU2001260192A1 (en) | Glycinamides | |
AU2001236058A1 (en) | Preparations for chondrogenesis | |
AU2001278975A1 (en) | Alpha-conotoxin peptides |